Clinical Trial Update: Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2) [Phase 3]

View source ↗

Summary

Phase 3 trial update for empagliflozin added to insulin in type 1 diabetes over 52 weeks (EASE-2) with completed status and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 1 | Phase 3 | Status: COMPLETED | Results posted: 2018-11-20